Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are frequently employed to counteract the detrimental effects of proteinuria on glomerular diseases. However, the effects of ARBs remain poorly examined in pediatric patients with immunoglobulin A (IgA) nephropathy. Herein, we evaluated the efficacy and safety of losartan, an ARB, in pediatric IgA nephropathy with proteinuria. Methods: This prospective, single-arm, multicenter study included children with IgA nephropathy exhibiting proteinuria. Changes in proteinuria, blood pressure, and kidney function were prospectively evaluated before and 4 and 24 weeks after losartan administration. The primary endpoint was the difference in proteinuria between baseline and 24 weeks. Results: In total, 29 patients were enrolled and received losartan treatment. The full analysis set included 28 patients who received losartan at least once and had pre- and post-urinary protein to creatinine ratio measurements (n=28). The per-protocol analysis group included 22 patients who completed all scheduled visits without any serious violations during the study period. In both groups, the mean log (urine protein to creatinine ratio) value decreased significantly at 6 months. After 24 weeks, the urinary protein to creatinine ratio decreased by more than 50% in approximately 40% of the patients. The glomerular filtration rate was not significantly altered during the observation period. Conclusions: Losartan decreased proteinuria without decreasing kidney function in patients with IgA nephropathy over 24 weeks. Losartan could be safely employed to reduce proteinuria in this patient population. ClinicalTrials.gov trial registration (NCT0223277)
Abstract
Purpose: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are frequently employed to counteract the detrimental effects of proteinuria on glomerular diseases. However, the effects of ARBs remain poorly examined in pediatric patients with immunoglobulin A (IgA) nephropathy. Herein, we evaluated the efficacy and safety of losartan, an ARB, in pediatric IgA nephropathy with proteinuria. Methods: This prospective, single-arm, multicenter study included children with IgA nephropathy exhibiting proteinuria. Changes in proteinuria, blood pressure, and kidney function were prospectively evaluated before and 4 and 24 weeks after losartan administration. The primary endpoint was the difference in proteinuria between baseline and 24 weeks. Results: In total, 29 patients were enrolled and received losartan treatment. The full analysis set included 28 patients who received losartan at least once and had pre- and post-urinary protein to creatinine ratio measurements (n=28). The per-protocol analysis group included 22 patients who completed all scheduled visits without any serious violations during the study period. In both groups, the mean log (urine protein to creatinine ratio) value decreased significantly at 6 months. After 24 weeks, the urinary protein to creatinine ratio decreased by more than 50% in approximately 40% of the patients. The glomerular filtration rate was not significantly altered during the observation period. Conclusions: Losartan decreased proteinuria without decreasing kidney function in patients with IgA nephropathy over 24 weeks. Losartan could be safely employed to reduce proteinuria in this patient population. ClinicalTrials.gov trial registration (NCT0223277)
참고문헌 (32)
- Chapter 10, "Immunoglobulin A nephropathy", Kidney Int Suppl(2011), 2, pp.209~217 (2012)
- Nakamura T, "Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy", Am J Nephrol, 20, pp.373~379 (2000)
- Young-Il JO, "Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial", The Korean Journal of Internal Medicine, 31(2), pp.335~343 (2016), 대한내과학회[DOI]
- Nakanishi K, "Efficacy and safety of lisinopril for mild childhood IgA nephropathy : a pilot study", Pediatr Nephrol, 24, pp.845~849 (2009)
- Hogg RJ, "Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy", Am J Kidney Dis, 66, pp.783~791 (2015)
- Masutani K, "Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy : a randomized controlled trial", Clin Exp Nephrol, 20, pp.896~903 (2016)
- Vecchio M, "Immunosuppressive agents for treating IgA nephropathy", Cochrane Database Syst Rev, (8) (2015)[DOI]
- Le W, "Long-term renal survival and related risk factors in patients with IgA nephropathy : results from a cohort of 1155 cases in a Chinese adult population", Nephrol Dial Transplant, 27, pp.1479~1485 (2012)
- Berthoux F, "Predicting the risk for dialysis or death in IgA nephropathy", J Am Soc Nephrol, 22, pp.752~761 (2011)
- Graciano ML, "Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis", J Am Soc Nephrol, 15, pp.1805~1815 (2004)
- Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
- Xie Y, "Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study", Am J Med Sci, 341, pp.367~372 (2011)
- Horita Y, "Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy", Ren Fail, 29, pp.441~446 (2007)
- Shimizu A, "Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy", Hypertens Res, 31, pp.1711~1717 (2008)
- Chandar J, "Angiotensin blockade as sole treatment for proteinuric kidney disease in children", Nephrol Dial Transplant, 22, pp.1332~1337 (2007)
- Mahmoudpour SH, "Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors", Pharmacogenet Genomics, 27, pp.112~119 (2017)
- Webb NJ, "Randomized, double-blind, controlled study of losartan in children with proteinuria", Clin J Am Soc Nephrol, 5, pp.417~424 (2010)
- Ellis D, "Antihypertensive and renoprotective efficacy and safety of losartan : a long-term study in children with renal disorders", Am J Hypertens, 17, pp.928~935 (2004)
- Shima Y, "Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy : a randomized controlled trial(JSKDC01 study)", Pediatr Nephrol, 34, pp.837~846 (2019)
- Webb NJ, "Losartan and enalapril are comparable in reducing proteinuria in children", Kidney Int, 82, pp.819~826 (2012)
- Litwin M, "Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors", Pediatr Nephrol, 21, pp.1716~1722 (2006)
- D’Amico G., "Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature", Am J Kidney Dis, 20, pp.315~323 (1992)
- Kusumoto Y, "Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese", Clin Nephrol, 28, pp.118~124 (1987)
- Higa A, "Long-term outcome of childhood IgA nephropathy with minimal proteinuria", Pediatr Nephrol, 30, pp.2121~2127 (2015)
- Nozawa R, "Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation", Clin Nephrol, 64, pp.171~179 (2005)
- Haas M, "IgA nephropathy in children and adults : comparison of histologic features and clinical outcomes", Nephrol Dial Transplant, 23, pp.2537~2545 (2008)
- Shima Y, "Spontaneous remission in children with IgA nephropathy", Pediatr Nephrol, 28, pp.71~76 (2013)
- Suh JS, "Remission of proteinuria may protect against progression to chronic kidney disease in pediatric-onset IgA nephropathy", J Clin Med, 9, pp.2058~ (2020)
- Shahinfar S, "A double-blind, dose-response study of losartan in hypertensive children", Am J Hypertens, 18(2 Pt 1), pp.183~190 (2005)
- Wuhl E, "Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure", Kidney Int, 66, pp.768~776 (2004)
- Sakallı H, "Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients", Exp Clin Transplant, 12, pp.310~313 (2014)
- Webb NJ, "A randomized, open-label, dose-response study of losartan in hypertensive children", Clin J Am Soc Nephrol, 9, pp.1441~1448 (2014)